To hear about similar clinical trials, please enter your email below
Trial Title:
IMRT/Pemetrexed/Cisplatin in Esophageal Cancer
NCT ID:
NCT01630174
Condition:
Esophageal Cancer
Conditions: Official terms:
Esophageal Neoplasms
Conditions: Keywords:
IMRT,Pemetrexed,Cisplatin , Esophageal Cancer
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Summary:
To evaluate the effect of concomitant late course accelerated hyperfractionation
radiochemotherapy with pemetrexed and cisplatin in patients with esophagus cancer
Criteria for eligibility:
Study pop:
esophagus cancer patients
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
1. Signed informed consent; 2.Acquired pathological diagnosis; 3.Life expectancy≥6
months; 4.Age:18-75 years, male or female; 5.General state of health: ECOG 0-1
grade; 6.Without any chemotherapy or radiotherapy; 7.Subjects meet the following
criteria for the clinical laboratory:HG≥100g/L, WBC≥3.5X109 /L, neutrophilic
leukocyte≥1.5X109,PLT100X109 /L。CR≤1.5 x N，TB≤2.5XN，AST and ALT≤2.5xN，AKP≤2.5XN.
Exclusion Criteria:
- 1.Serious infection; 2.Uncontrollable diabetes; 3.Other serious diseases, such as
myocardial infarction in 6 months; 4. Participated other clinical trials in 4 weeks
or at present
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Shandong Cancer hospital and institute
Address:
City:
Jinan
Zip:
250017
Country:
China
Status:
Recruiting
Investigator:
Last name:
Baosheng Li, Ph.D.
Email:
Principal Investigator
Investigator:
Last name:
Zhongtang Wang, M.D.
Email:
Sub-Investigator
Start date:
October 2009
Lead sponsor:
Agency:
Shandong Cancer Hospital and Institute
Agency class:
Other
Source:
Shandong Cancer Hospital and Institute
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01630174
